摘要
阿帕替尼是一种小分子的酪氨酸激酶抑制剂,其通过高度选择性地作用于血管内皮细胞生长因子受体-2强效抑制肿瘤血管生成。阿帕替尼还可以阻滞细胞周期和逆转耐药。临床研究表明阿帕替尼对多种恶性肿瘤有效,如胃癌、非小细胞肺癌、乳腺癌等,具有较好的客观有效率和生存获益,同时具有良好的安全性和耐受性。
Apatinib is a kind of antiangiogenesis drug of small molecular tyrosine kinase inhibitor,which can strongly against tumor angiogenesis by inhibiting vascular endothelial growth factor receptor 2 with highly selectivity.Apatinib can block cell cycle and reverse drug resistance.Clinical studies have shown that Apatinib is effective for many malignant tumors,including non-small cell lung cancer,breast cancer and gastric cancer,which has encouraging objective response rate and survival benefit.Apatinib also has good safety and tolerance.
作者
黄海
毕锋
Huang Hai;Bi Feng(Department of Abdominal Oncology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《国际肿瘤学杂志》
CAS
2019年第1期45-48,共4页
Journal of International Oncology
基金
国家自然科学基金(81872020).
